Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Dr. Reddy's Folds Drug Discovery Arm
by Jean-François Tremblay
June 1, 2009
| A version of this story appeared in
Volume 87, Issue 22
Indian generics producer Dr. Reddy's Laboratories will abandon its proprietary drug discovery efforts but will remain active in drug development. The firm will transfer its drug discovery staff and facilities in Hyderabad to its contract research subsidiary Aurigene. As part of the reorganization, Dr. Reddy's will close an R&D lab in Atlanta. The firm says it will still conduct drug development work by licensing promising drug candidates from Aurigene and others.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter